MENU
OCT 28 - 29 2020

Advancing the future of diagnostics

17 June 2021
 
Accelerating Diagnostic Test Development
 
Register now for the virtual open day
 
Each step in a diagnostic test’s journey—from raw material extraction to patient administration—can influence outcomes.  Advances in molecular biology, immunodiagnostics and rapid point-of-care (POC) testing are transforming diagnostics. New products and support services are providing the critical tools and components which enable clinicians to detect specific biomarkers and target treatments, ultimately resulting in better patient outcomes.
 
Recent events have increased the global focus and commitment to commercializing diagnsotic tests as quickly as possible as well as the challenges the industry has faced in developing and bringing these diagnostic tests to market in exceptional circumstances.  A wealth of technology, diverse expertise in areas such as material science, biochemistry, virology as well as a robust supply of critical components are fundamental to the successful development of every test.  Optimizing assays and kits for high sensitivity and accuracy is a common goal for all those involved in the development process. The need for close collaboration between diagnostic developers and component and material providers has never been stronger.
 
We invite you to our thought-provoking and interactive virtual open day showcasing recently launched products, solutions and services supporting the development of diagnostic assays and kits. Incorporating a program of webinars, panel discussion and new for the open day, a live keynote Q&A session. You will also be able to live chat with our product experts. 
 
If you would like to pre-schedule a 15 minute meeting with one of our Cytiva experts please click here.
 
Event tracks available:
  1. Lateral flow design considerations

High performance, diagnostic rapid point-of-care (POC) flow-based tests can quickly deliver reliable results in challenging settings. When designing a new test and designing out a component in an existing test-what are the key considerations and what will be needed in the future?

  1. Accelerating diagnostic development with custom and design services

Commercializing a test or assay as quickly as possible is critical to success. Find out how diagnostic design services, lyophilization and custom capabilities can provide capacity, resources and expertise to improve speed to market now and in the future.

  1. Collaborating for effective diagnostic development

Strategic collaboration enables the development of diagnostic tests, assays and service for a wide range of applications. Hear about recent collaborations that have resulted in successful test development and set a path for future development.

  1. Simplifying your next-generation sequencing (NGS) workflow

High throughput NGS techniques are revolutionizing genomics from massively parallel whole genome sequencing to targeted sequencing approaches. Find out how to simplify your sequencing approaches for more detailed data, better diagnosis, and more targeted treatments to address current and future demands.

  1. Exploring single-cell omics opportunities

Recent technological advancements have made single-cell omics an increasingly powerful tool for diagnosis, treatment response prediction, and treatment selection, particularly for cancer. Learn about the opportunities for improving results in this growing field.

  1. Optimizing nucleic acid isolation

Recent years have seen the development and adaptation of several approaches for nucleic acid isolation, aiming to improve speed, throughput, and reproducibility. Find out how to optimize results, particularly for liquid biopsy and viral samples now and in the future.

 

Sessions will be available for on-demand viewing immediately following the live broadcast.

 


Speakers

Show Resources
Webinars

Click on 'Watch on Demand' button to view the webinars within the summit or click on each webinar below to go directly to that webinar.

  • Lateral flow manufacturing strategies and scale-up towards Point-of-Care (POC) testing
    Dr. Chris Fronczek
    Application Scientist, BioDot, Inc
  • Detection of mutations from liquid biopsies - applications in cancer diagnostics
    Monika Seidel
    Senior Development Scientist - Genomics and Cellular Research, Cytiva
  • Minimizing risks of security of supply
    David Raw
    Supplier Risk Management Leader, Cytiva
  • Accelerating rapid test development for COVID-19 through manufacturing scale up and open collaboration
    OCT 28, 2020 5:00 PM GMT, 10:00 AM PDT, 1:00 PM EDT
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • The varied application of Dried Blood Spot (DBS) sample collection during the COVID-19 Pandemic
    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
  • Klaus Hochleitner, PhD, Brendan O'Farrell, PhD, Darren Rowles, David Wilson
    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    Darren Rowles
    President and CEO, Sona Nanotech
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • Eliminate temperature sensitivity with lyophilization technology
    Amy Webster
    Custom Manufacturing Service Leader, Genomics and Diagnostic Solutions, Cytiva
  • Improving cell health for single-cell proteomic analysis and immune monitoring
    Sean Mackay
    CEO & Co-Founder, Isoplexis
  • Using 3D in vitro tumoroids for personalized medicine
    Marilena Loizidou
    Deputy Director of the Division of Surgery and Interventional Science, Head of the Department of Surgical Biotechnology, Professor of Cancer Nanotechnology, University College London (UCL)
  • Applications of high throughput gene expression profiling in early drug discovery
    Pieter Mestdagh, PhD
    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
  • Broaden your applications with magnetic bead conjugation
    Tom Lyons
    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
  • Characterization and selection of antibodies for precision diagnostics using Biacore surface plasmon resonance technology
    Anja Drescher
    Senior Application Specialist for Biacore systems, Cytiva
  • Lateral flow assay development from lab-based assay to diagnostics test prototype: introducing Cytiva's development services platform
    Lee Jenkins
    Senior Product Leader, Cytiva
  • Gabriel Fernandez de Pierola, Chris Norey
    Gabriel Fernandez de Pierola
    General Manager, Genomics & Diagnostic Solutions, Cytiv...
    Chris Norey
    R&D Leader, Genomics and Cellular Research, Cytiva
  • Optimizing cell viability for single-cell omics
    Priya Hari
    Post Doctoral Genomics Research Fellow, Cytiva
  • The importance of working with your CMO during product development
    Jonathan Thomas
    Head of Contract Sales, Abingdon Health
  • Approaches to sample preparation
    Stefanie Stepanow, Dr. rer nat
    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
  • Simplifying component Selection in Lateral Flow Assay Development
    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
  • Lateral flow design considerations
  • Simplifying component Selection in Lateral Flow Assay Development
    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
  • The importance of working with your CMO during product development
    Jonathan Thomas
    Head of Contract Sales, Abingdon Health
  • Characterization and selection of antibodies for precision diagnostics using Biacore surface plasmon resonance technology
    Anja Drescher
    Senior Application Specialist for Biacore systems, Cytiva
  • Klaus Hochleitner, PhD, Brendan O'Farrell, PhD, Darren Rowles, David Wilson
    Klaus Hochleitner, PhD
    Global Technology Lead, Diagnostics, Cytiva
    Brendan O'Farrell, PhD
    President and Co-Founder, DCN Diagnostics
    Darren Rowles
    President and CEO, Sona Nanotech
    David Wilson
    Commercial Director, Diagnostics, Avacta Life Sciences
  • Lateral flow manufacturing strategies and scale-up towards Point-of-Care (POC) testing
    Dr. Chris Fronczek
    Application Scientist, BioDot, Inc
  • Optimizing nucleic acid isolation
  • Approaches to sample preparation
    Stefanie Stepanow, Dr. rer nat
    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
  • Gabriel Fernandez de Pierola, Chris Norey
    Gabriel Fernandez de Pierola
    General Manager, Genomics & Diagnostic Solutions, Cytiv...
    Chris Norey
    R&D Leader, Genomics and Cellular Research, Cytiva
  • The varied application of Dried Blood Spot (DBS) sample collection during the COVID-19 Pandemic
    Dr. Zahidul Mondle
    Lead Technical Product Specialist, Cytiva
  • Exploring single-cell omics opportunities
  • Optimizing cell viability for single-cell omics
    Priya Hari
    Post Doctoral Genomics Research Fellow, Cytiva
  • Using 3D in vitro tumoroids for personalized medicine
    Marilena Loizidou
    Deputy Director of the Division of Surgery and Interventional Science, Head of the Department of Surgical Biotechnology, Professor of Cancer Nanotechnology, University College London (UCL)
  • Improving cell health for single-cell proteomic analysis and immune monitoring
    Sean Mackay
    CEO & Co-Founder, Isoplexis
  • Accelerating diagnostic development with custom and design services
  • Lateral flow assay development from lab-based assay to diagnostics test prototype: introducing Cytiva's development services platform
    Lee Jenkins
    Senior Product Leader, Cytiva
  • Broaden your applications with magnetic bead conjugation
    Tom Lyons
    Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
  • Eliminate temperature sensitivity with lyophilization technology
    Amy Webster
    Custom Manufacturing Service Leader, Genomics and Diagnostic Solutions, Cytiva
  • SIMPLIFYING YOUR NGS WORKFLOW
  • Applications of high throughput gene expression profiling in early drug discovery
    Pieter Mestdagh, PhD
    Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
  • Detection of mutations from liquid biopsies - applications in cancer diagnostics
    Monika Seidel
    Senior Development Scientist - Genomics and Cellular Research, Cytiva
  • Collaborating for effective diagnostic development
  • Minimizing risks of security of supply
    David Raw
    Supplier Risk Management Leader, Cytiva
About Us

Advancing the development and manufacture of therapeutics

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.

Improving access to life-changing therapies that transform human health

Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.

Cytiva is a global life sciences leader with over 7000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.

  • We operate in 40 countries and territories covering Europe, Asia, North and Latin America, and the Middle East.
  • 7,000 associates are dedicated to our mission to advance and accelerate therapeutics.
  • We host 11 customer-centered innovation facilities across Asia, Europe and the Americas to carry ideas through to commercial development

Find out more at Cytiva.com

Keynote Session

We are delighted to be hosting a Q&A at the Diagnostics virtual open day on 17 June 2021. 

 

If you have questions on diagnostic test development, we want to hear from you. Submit your questions to our team of experts on topics including lateral flow assay development, diagnostic design and custom services and optimizing sample preparation and purification with magnetic beads...

 

We will do our best to answer as many of the questions as possible during the open day.

 

Submit your questions here [https://forms.office.com/r/HFH3kieb5h]

 

We have also compiled the most popular questions that were submitted by attendees at the Diagnostics Virtual Summit in October 2020 which we will also answer during the event.

Speakers

  • Anja Drescher
    Senior Application Specialist for Biacore systems, Cytiva
    Biography

      Anja is a senior application specialist for Biacore systems with over 17 years’ experience supporting and educating Biacore users in Germany. Anja’s interests focus on development of new or challenging applications using optical biosensors including the analysis of complex sample matrices. Anja’s background is in biotechnology engineering and she received her PhD in molecular Biology from Humboldt University in Berlin.

    • Gabriel Fernandez de Pierola
      General Manager, Genomics & Diagnostic Solutions, Cytiva
      Biography

        Gabriel Fernandez de Pierola is the Genomics & Diagnostic Solutions General Manager at Cytiva, since 2017. He is responsible for the development and commercialization of products and services that enable automatable, cost-effective and reliable technologies for kit developers and end users mainly focusing on genomics. Previously he was the Global Commercial Finance manager for the GE Healthcare Bioprocess business. Gabriel started his career in the GE Capital Financial Management Program in 1999. Gabriel holds a Bachelor of Business Administration degree from ICADE (Spain) and Reims Management School (France).

      • Dr. Chris Fronczek
        Application Scientist, BioDot, Inc
        Biography

          Dr. Christopher Fronczek is currently an Application Scientist in Research and Development for BioDot, Inc. He received his B.S. in Biological Engineering in 2010 from Louisiana State University and Ph.D. in Biomedical Engineering in 2013 from the University of Arizona. He has also worked towards the development of point-of-care diagnostics and has worked as a Postdoctoral Fellow in Analytical Chemistry. Since joining BioDot in 2016, his area of expertise has been low-volume dispensing and liquid handling for biosensors and various other point-of-care diagnostic devices.

        • Priya Hari
          Post Doctoral Genomics Research Fellow, Cytiva
          Biography

            Priya Hari is a Postdoctoral Genomics Research Fellow at Cytiva with advanced skills in research, cell culture and science communication and is heavily endorsed by the University of Edinburgh. Priya holds a BSc in Medical Biochemistry and a PhD in Cellular Senescence and Tumour Suppression. Alongside her academic achievements, Priya has also been an active STEM Ambassador for over eight years and has published five papers in a range of application areas.

          • Klaus Hochleitner, PhD
            Global Technology Lead, Diagnostics, Cytiva
            Biography

              Dr. Hochleitner is a cell and molecular biologist and has covered different roles in the field of membrane research and development, and developing diagnostic tests on solid surfaces. He is working in the field of lateral flow tests for more than 25 years.

            • Lee Jenkins
              Senior Product Leader, Cytiva
              Biography

                Part of the Senior Management team within the Whatman business area of Cytiva, with overall responsibility for the performance of a large portfolio of products and services, primarily focused on the diagnostic rapid testing market. Experience of involvement with diagnostic development companies for over 5 years and part of the Cytiva (formerly GE Life Sciences) business for over 9 years.

              • Marilena Loizidou
                Deputy Director Division of Surgery and Interventional Science, University College London (UCL) ...
                Biography

                  Marilena Loizidou is Deputy Director of the Division of Surgery and Interventional Science, Head of Department of Surgical Biotechnology and a Professor of Cancer Nanotechnology at University College London (UCL).

                  Marilena Loizidou uses nanotechnology tools in cancer pharmacology research. Her main focus has been in the field of novel imaging and targeted therapeutics in solid tumors, mainly colorectal cancer, with a focus on the role of the fibrotic cancer stroma. Marilena co-invented tumoroids, 3D in vitro cultures of cancer which mimic the composition and architecture of solid tumors. Today tumoroids are being developed as platforms for therapeutics and for stratified medicine.

                • Tom Lyons
                  Custom Projects Leader, Genomics and Diagnostic Solutions, Cytiva
                  Biography

                    Tom Lyons is Custom Projects Leader at Cytiva, managing custom Sera-Mag™ formulations and conjugation projects. Since graduating from the University of East Anglia with a Masters in Analytical Chemistry with Forensic Sciences in 2008, Tom has gained experience in many research and development roles including British BioCell where he developed lateral flow immunodiagnostic devices and Binx Healthcare (formerly Atlas Genetics), where he developed enzyme stabilization formulations and managed the bulk reagent formulating process. Tom is trained in PRINCE2 project management with a focus on the transfer to manufacture of formulations for InVitro Diagnostic Devices with CE and FDA regulator frameworks.

                  • Sean Mackay
                    CEO & Co-Founder, Isoplexis
                    Biography

                      Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy-to-use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

                      Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information.  Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored several publications centered around immune medicines and holds patents for a number of single-cell products worldwide.

                    • Pieter Mestdagh, PhD
                      Senior Scientist at Biogazelle and Associate professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium
                      Biography

                        Pieter Mestdagh, PhD is a Senior Scientist at Biogazelle, as well as Associate Professor at the Faculty of Medicine and Health Sciences, Ghent University, Belgium. He holds Masters degrees in industrial Engineering and Biochemistry (2004), and Bioscience Engineering and Cell and Gene Biotechnology (2006), as well as PhD in Biomedical Sciences (2011). He is the author of more than 100 scientific articles in international journals, as well as the owner of six European Patents.

                      • Dr. Zahidul Mondle
                        Lead Technical Product Specialist, Cytiva
                        Biography

                          Dr. Zahidul Mondle is a Lead Technical Product Specialist at Cytiva. He has decades of hands on experience in developing molecular diagnostics, lateral flow assays, and immunoassays. He worked at Pfizer in vaccine development as an analytical scientist before joining Cytiva. Zahidul hold an MBA and a PhD in Biochemistry.

                        • Chris Norey
                          R&D Leader, Genomics and Cellular Research, Cytiva
                          Biography

                            Dr. Chris Norey is an R&D Leader with over 25 years’ experience in the life sciences industry after gaining a PhD in Biochemistry and Molecular Biology. For the past 10 years Dr. Norey has lead teams responsible for launching over 25 new products, including instrumentation and reagent and consumable products, most recently the Sera-Xtracta™ genomic and cell free nucleic acid isolation kits. He currently leads the genomics R&D team at Cytiva focused on delivering tools for the growing field of genetic based diagnostic applications.

                          • Brendan O'Farrell, PhD
                            President and Co-Founder, DCN Diagnostics
                            Biography
                              Dr O'Farrell has worked in the rapid diagnostics field for over 25 years and has been involved in over 200 product development programs in that time. He has wide experience in the development, manufacturing and commercialization of rapid diagnostics in a variety of industry verticals. In 2005 he co-founded DCN Diagnostics, a market leading provider of contract development and manufacturing services to the rapid diagnostics business, where is holds the role of President.
                            • David Raw
                              Supplier Risk Management Leader, Cytiva
                              Biography

                                David Raw is the Supplier Risk Management Leader at Cytiva (formerly GE Healthcare Life Sciences) and has worked in supply and sourcing roles in healthcare for more than 13 years. David is passionate about positioning security of supply as a value-based differentiator and a clear value driver of success for patients and Biopharma customers. David holds an MBA in Business Strategy, Supply Chain Management and is also a student mentor/coach at Birmingham University in the UK.

                              • Darren Rowles
                                President and CEO, Sona Nanotech
                                Biography
                                  A commercially-minded scientist, Darren joined Sona after 14 years' experience in the diagnostic and nanoparticle industry. He previously worked for one of the leading providers of technologies to the global diagnostics market, where he specialised in product manufacture and development in the area of noble metal nanoparticles and lateral flow diagnostics. Darren is a key opinion leader at industry seminars and conferences and acts as an advisory board member to the World Gold Council. Darren has a BSC in Biomedical Science and Toxicology from University of Wales Institute Cardiff and a Master of Business Administration from University of Bath.
                                • Monika Seidel
                                  Senior Development Scientist - Genomics and Cellular Research, Cytiva
                                  Biography

                                    Monika Seidel is the scientific lead on new product development from conception throughout feasibility to manufacturing handover. She has extensive knowledge of liquid biopsy-based diagnostic applications including explain ddPCR (ddPCR) and NGS and expertise in molecular biology, biochemistry, immunology-related techniques, mass spectrometry and stem cell biology. Monika’s research has focused on dissecting molecular mechanisms of human diseases in the field of genomics, proteomics and lipidomics including explain iPSc based(iPSc) modelling of motor neuron degeneration, structure function relationship studies in Ryanodine Receptor 2 associated with sudden cardiac death and siRNA-based high content and high throughput screening for identification of molecular targets and signaling pathways of anti-cancer drugs. She has an M.Sc. degree in Biotechnology, B.Sc. in Organic Chemistry and holds a PhD in Medical Sciences from the University of Cardiff, UK.

                                  • Stefanie Stepanow, Dr. rer nat
                                    NGS Core Facility Manager, Private Molecular Diagnostic Lab, Cologne, Germany.
                                    Biography
                                      Dr Stefanie Stepanow is an NGS core facility manager in a private molecular diagnostic lab in Cologne, Germany. She is responsible for the establishment and validation of new NGS assays as well as monitoring and optimization of current NGS workflows. For almost 9 years, Stefanie has worked routinely with different NGS techniques (Illumina™, Ion Torrent™) and a wide range of sample materials while gaining experience in optimizing NGS workflows to achieve meaningful results from difficult materials. Previously, she worked as a scientist in an NGS core facility with focus on clinical and biological research in Duesseldorf, where she established and standardized the NGS techniques and attained lab accreditation.
                                    • Jonathan Thomas
                                      Head of Contract Sales, Abingdon Health
                                      Biography

                                        Graduating from Aberystwyth University with Joint Hons Microbiology & Biochemistry, Jon started his career as a Microbiologist at Revlon Manufacturing UK Ltd where he was first involved in developing rapid tests. This was followed by several years in R&D at companies developing ATP bioluminescence based assays before moving into Project Management in 1998. For the last 20 years Jon has held commercial roles in the Biotechnology, Pharma, IVD and Life Science sectors and is currently the Head of Contract Sales at Abingdon Health.

                                      • Amy Webster
                                        Custom Manufacturing Service Leader, Genomics and Diagnostic Solutions, Cytiva
                                        Biography
                                          Amy Webster is Custom Projects Leader at Cytiva, managing custom Lyo-Stable formulations and custom plates projects. Since graduating from the University of Bath with a first class honours MChem in Chemistry with Drug discovery in 2011, Amy has gained experience with Binx Healthcare (formerly Atlas Genetics), developing and stabilizing reagent formulations and integrating point of care assays onto automated custom devices.  She has also worked for Enigma Diagnostics on the transfer of diagnostic tests and machine builds from R&D to operations as well as validating manufacturing methods and QC tests.
                                        • David Wilson
                                          Commercial Director, Diagnostics, Avacta Life Sciences
                                          Biography
                                            David brings to Avacta over 25 years international experience in business development, marketing and sales management in the in-vitro diagnostic medical devices industry, having held senior commercial and Board level positions in global corporations, angel and venture capital funded start-ups and a sector specific trade association. He is currently a Board member for two early-stage diagnostic businesses developing novel point of care diagnostic testing platforms, and has served on the Executive Committee of the British In Vitro Diagnostics Association (BIVDA). David has a BSc (Hons) in Biochemistry and Microbiology from the University of St. Andrews and a MBA from the Open University Business School.
                                          Collaborators

                                          Abingdon Health is a technology-enabled lateral flow diagnostics company providing leading-edge rapid testing solutions to a multi-industry, global client base. Abingdon Health provides lateral flow assay development and smartphone reader solutions alongside Europe’s largest rapid test manufacturing capacity. A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.

                                          Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost. Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONTM drug candidate, a targeted form of the standard-of-care Doxorubicin, into the clinic by the first half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics business unit works with partners world-wide to develop Affimer proteins for evaluation by those third parties with the objective of establishing royalty bearing license deals with a particular focus on the diagnostics sector. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

                                           

                                          BioDot is the leading provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R&D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets. Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications. BioDot, founded in 1994, is based in Irvine, California and has international offices in Europe and Asia.

                                           

                                          Biogazelle is a Contract Research Organization (CRO) specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We hold a unique forefront position in the application of quantitative PCR, digital PCR and dedicated RNA sequencing workflows, optimized for quantification of coding and non-coding genes, on precious clinical samples such as liquid biopsies and formalin-fixed, paraffin-embedded (FFPE) tissues. Our aim is to accelerate the development of therapeutics, including small molecules, RNA targeted drugs, and adoptive cell therapies.

                                           

                                          IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its uniquely correlative, award-winning, single-cell proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise and personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine and Fierce, are used globally to advance the field of immune biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.

                                          Help

                                          General Labroots Questions

                                          email support@labroots.com  

                                          Virtual Events and Webinars

                                          Supported Configurations

                                          • Operating System Internet Explorer Firefox Chrome Safari
                                            Vista IE8+ FF10+ Chrome15+
                                            Windows 7 IE8+ FF10+ Chrome15+
                                            Windows 8 IE10 FF10+ Chrome15+
                                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                                          • Cookie settings: session cookies enabled
                                          • Browser configuration must have JavaScript enabled
                                          • Adobe Flash player 10.2 or later

                                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                          Internet Connection

                                          • A minimum of 100Kbps is recommended for audio-only events
                                          • A minimum of 300Kbps is recommended for speaker on-video events

                                          Computer Equipment

                                          • Screen Resolution: Minimum 1024x768
                                          • Video Card: 65,000 colors minimum
                                          • Sound card and speakers (or headphones) for hearing webcast in full format
                                          • Audio Card: 16-bit minimum
                                          • RAM: 512MB of free RAM

                                          Firewall Protocol

                                          • HTTP on port 80 or HTTPS on port 443
                                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                          Work-At-Home Attendees

                                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                          For A Seamless Experience

                                          When using a mobile device, FREE Mobile Apps are available:

                                          - For viewing Webinars:

                                          - For viewing Virtual Events

                                          Attendee Guide

                                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                          Virtual Event and Webinar Support:

                                          Continuing Education (CME/CE) Support

                                          Show Resources